Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: A pilot study

Current Medical Research and Opinion

Volumn 23, Issue 7, 2007, Pages 1667-1672

  Brandes, David W ^a   Bigley, Kim ^b   Hornstein, William ^c   Cohen, Hart ^d   Au, William ^e   Shubin, Richard ^f  

^a Northridge MS Center   (United States)

^b Renown Health   (United States)

^c Fountain Valley Regional Hospital and Medical Center   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e Neurological Consultants Medical Group   (United States)

^f Neurology Consultants   (United States)

Author keywords

Flu like symptoms; Interferon beta; Management strategies; Multiple sclerosis

Indexed keywords

ANALGESIC AGENT; BETA1A INTERFERON; IBUPROFEN; INTERFERON BETA SERINE; PARACETAMOL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; ETHNICITY; FEMALE; FLU LIKE SYNDROME; HUMAN; MALE; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL;

ACETAMINOPHEN; ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANALGESICS, NON-NARCOTIC; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IBUPROFEN; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PILOT PROJECTS;

EID: 34547236676     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210741     Document Type: Article

References (14)

1. Disease management consensus statement. New York, NY: National Multiple Sclerosis Society. Available from http://www.nationalmssociety.org/Sourcebook- Early.asp [Last accessed 28 Nov 2006]
2. Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis. Review of adverse effect profiles. CNS Drugs 2005;19:1-14
3. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
4. Jacobs LD, Cookfair DL, Rudick RA, et al., and the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94
5. PRISMS (Prevention of Relapses and Disability by Interferon B-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
6. Mohr DC, Likosky W, Boudewyn AC, et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 1998;4:487-9
7. Tremlett HL, Oger J. Interrupted therapy. Stopping and switching of the β-interferons prescribed for MS. Neurology 2003;61: 551-4
8. O'Rourke KET, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50
9. Rio J, Nos C, Marzo ME, et al. Low-dose steroids reduce flu-like symptoms at the initiation of IFNβ-1b in relapsing-remitting MS. Neurology 1998;50:1910-2
10. Reess J, Haas J, Gabriel K, et al. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX®) therapy. Mult Scler 2002;8:15-8
11. Río J, Nos C, Bonaventura I, et al. Corticosteroids, ibuprofen, and acetaminophen for IFNβ-la flu symptoms in MS. A randomized trial. Neurology 2004;63:525-8
12. Rice GPA, Ebers GC, Lublin FD, et al. Ibuprofen treatment versus gradual introduction of interferon β-1b in patients with MS. Neurology 1999;52:1893-5
13. Wroe SJ. Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. J Int Med Res 2005;33:309-18
14. Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8:227-36